-
Levofloxacin, a wholly-owned subsidiary of Prologue Pharmaceuticals, obtained CEP certificate
Time of Update: 2021-08-06
On July 21, Prologue Pharmaceuticals issued an announcement stating that Prokangyu Pharmaceutical, a wholly-owned subsidiary, had received a CEP certificate for levofloxacin API issued by the European Medicines Quality Administration .
It is the levofloxacin isomer of ofloxacin, and its in vitro antibacterial activity is about twice that of ofloxacin .
-
The Phase I clinical trial application of Deqi Pharmaceutical ATG-101 was approved in Australia
Time of Update: 2021-08-06
announced that the Bellberry Human Research Ethics Committee (HREC) of Australia has approved ATG-101 for the treatment of metastatic or advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL).
-
Biogen and Nuocheng Jianhua reached a license and cooperation agreement for obritinib, which is expected to treat multiple sclerosis
Time of Update: 2021-08-06
"Considering the complexity of MS and the characteristics of chronic diseases, we believe that the uniqueness of abutinib, both high selectivity and central nervous system (CNS) permeability, has potential clinical advantages compared with other BTK inhibitors ," said Alfred Sandrock, MD, head of Biogen’s research and development: “For more than 30 years, Biogen has been a leader in the field of MS research and currently has a leading MS drug portfolio .
-
Johnson & Johnson and 3 distributors agree to pay US$26 billion to reach an opioid settlement agreement
Time of Update: 2021-08-06
A few days ago, Johnson & Johnson and the three major drug distributors in the United States have agreed to pay a total of US$26 billion to reach a settlement with the plaintiff to resolve thousands of protracted opioid lawsuits .
-
Gale FASN Inhibitor Approved for Phase 3 Clinical Tumor Indication
Time of Update: 2021-08-06
On July 22, Gallée announced that the National Medical Products Administration (NMPA) of China has approved a Phase 3 clinical trial of ASC40 combined with bevacizumab in the treatment of patients with recurrent glioblastoma (rGBM) .
-
Yifan Pharmaceutical's wholly-owned subsidiary, cross-linked sodium hyaluronate injection received the notification of drug registration acceptance
Time of Update: 2021-08-05
On July 23, Yifan Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Beijing Xinyan Road, received on July 21 an overseas production of cross-linked sodium hyaluronate injection (trade name: Hyruan ONE®) issued by the National Medical Products Administration.
-
Difei Medical completes 200 million yuan financing lDG leads the investment to help lead the field of clinical molecular detection of pathogenic microorganisms
Time of Update: 2021-08-05
A two-pronged approach to laboratory testing qualification and registration application progress leads the industry In 2020, Difei Medical obtained the national first provincial clinical testing center for infectious pathogens clinical genetic testing project (conventional PCR method and high-throughput sequencing method) technical acceptance certificate, and at the same time passed the national clinical testing center and intermediate inspection many times Quality evaluation of mNGS microbiology in the hospital .
-
Yangtze River Pharmaceutical Group donated 20 million yuan to help Henan
Time of Update: 2021-08-05
In the past few days, the disasters caused by heavy rains in Henan have affected the hearts of the people across the country, as well as the hearts of all employees of Yangzijiang Pharmaceutical Group .
-
Eisai is pinched first / Chia Tai Tianqing Lunvatinib is approved!
Time of Update: 2021-08-05
Two negotiations for lenvatinib to cut the price of 80% to enter the medical insurance After lenvatinib is on the market, the domestic price is 16,800 yuan/box, the specification is 4mg, 30 capsules .
The medical insurance payment price of Bayer Sorafenib is 5700 yuan/box (0.
-
Yiling Pharmaceutical: Generic clarithromycin tablets passed the consistency evaluation
Time of Update: 2021-08-05
Lower respiratory tract infections (bronchitis, pneumonia); 2.
Upper respiratory tract infections (pharyngitis, sinusitis); 3.
Clarithromycin tablets are a category B product of the National Medical Insurance Catalog (2020 edition) and a product of the National Essential Medicines Catalog (2018 edition) .
-
Pfizer and Johnson & Johnson reach a settlement in the Remicade generic drug lawsuit
Time of Update: 2021-08-05
Pfizer initially filed a lawsuit against Johnson & Johnson in September 2017, claiming that in order to protect the market revenue of its blockbuster drug Remicade, Johnson & Johnson used "exclusive contracts" and other methods that violated the monopoly law to prevent suppliers and patients from using the Remicade generic drug Inflectra.
-
Two gene therapy trials failed, and Bojian's $542 million was lost
Time of Update: 2021-08-05
According to the second-quarter earnings report released by Biogen this Thursday, the company's two gene therapies BIIB111 and BIIB112 failed trials and lost up to 542 million U.
-
The first patient in the clinical trial of Guangshengtang hepatitis B treatment innovative drug GST-HG141 was enrolled
Time of Update: 2021-08-05
On July 23, Guangshengtang issued an announcement stating that the phase Ib clinical trial of the innovative hepatitis B treatment drug GST-HG141 has recently obtained the administrative permission of the "China Human Genetic Resources International Cooperative Scientific Research Approval", and the first patient will be in July 2021.
-
Alnylam, the king of commercialization of RNAi therapy, pushes blockbuster products to be launched soon
Time of Update: 2021-08-05
Recently, Alnylam Pharmaceuticals (hereinafter referred to as Alnylam) announced that the company's development of subcutaneous RNA interference (RNAi) therapy vutrisiran has been accepted by the FDA for the treatment of adult hereditary transthyretin-mediated (hATTR) amyloidosis Of polyneuropathy .
-
CD19/CD22 dual target! Reindeer Medical's second CAR-T product was approved for clinical use
Time of Update: 2021-08-05
On July 29, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the fully human anti-CD19 and CD22 autologous T cell injection (CT120) developed by Reindeer Medical has obtained the implied license for clinical trials and plans to develop Indications include: 1) CD19/CD22-positive relapsed/refractory acute B-lymphocytic leukemia (B-ALL); 2) relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL) .
CT120 is the second CAR-T product of Reindeer Medical.
-
Hualan Biotech's vaccine product was approved for clinical use
Time of Update: 2021-08-05
On the evening of July 27, Hualan Biological issued an announcement stating that it had recently received a report from its holding subsidiary Hualan Biological Vaccine Co.
-
Kangfang Bio/CP Tianqing PD-1 Paimrizumab will be approved soon
Time of Update: 2021-08-05
On July 30, the official website of the State Food and Drug Administration showed that the PD-1 monoclonal antibody jointly developed by Kangfang Biological and Chia Tai Tianqing (R&D code: AK105) listing application (acceptance number: CXSS2000022) has entered The "Administrative Approval" stage is expected to be approved by the National Food and Drug Administration in the near future.
-
Yan Yanna, Deputy General Manager of First Pharmaceutical, resigns
Time of Update: 2021-08-05
("First Pharmaceutical") issued an announcement stating that the board of directors had recently received a written resignation report from the company's deputy general manager Yan Yanna .
Yan Yanna requested to resign from the position of deputy general manager of the company due to personal reasons .
-
Entrepreneur Huikang & Weining Health: Terminate planning for major asset restructuring, stocks resume trading on July 26
Time of Update: 2021-08-05
On the evening of July 23, both Entrepreneur Huikang and Weining Health both issued an announcement stating that after careful research, the plan for major asset restructuring was terminated, and the company's shares will resume trading from the opening of the market on July 26 .
-
Pfizer acquires part of ARV-471 equity for 2.4 billion
Time of Update: 2021-08-05
[News event]: Pfizer announced today that it will acquire a partial interest in the estrogen receptor PROTAC drug ARV-471 developed by Arvinas, a pioneer in protein degradation, with a down payment of 650 million and a stock subscription of 350 million, plus 1.
